Alphatec (NASDAQ:ATEC) Hits New 52-Week Low on Analyst Downgrade

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) shares reached a new 52-week low on Monday after Weiss Ratings downgraded the stock from a sell (d-) rating to a sell (e+) rating. The stock traded as low as $6.78 and last traded at $6.8350, with a volume of 735,037 shares traded. The stock had previously closed at $7.07.

A number of other analysts have also recently commented on ATEC. BMO Capital Markets cut shares of Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 price target on the stock. in a research note on Friday, October 30th. Canaccord Genuity Group reduced their price objective on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Wall Street Zen cut shares of Alphatec from a “buy” rating to a “hold” rating in a report on Sunday, October 11th. Stephens assumed coverage on Alphatec in a research report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 target price on the stock. Finally, TD Cowen dropped their target price on Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.37.

View Our Latest Research Report on ATEC

Insider Activity

In other news, Director David Demski purchased 60,000 shares of the stock in a transaction dated Friday, October 30th. The shares were purchased at an average cost of $6.81 per share, with a total value of $408,600.00. Following the completion of the acquisition, the director owned 491,635 shares in the company, valued at $3,348,034.35. This represents a 13.90% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Miles acquired 115,000 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the transaction, the chief executive officer directly owned 5,893,551 shares of the company’s stock, valued at $51,922,184.31. This trade represents a 1.99% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 13.48% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Alphatec in the third quarter valued at approximately $24,355,000. Paradigm Capital Management Inc. NY bought a new stake in Alphatec during the second quarter valued at approximately $9,413,000. Bank of America Corp DE lifted its position in Alphatec by 26.9% during the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after purchasing an additional 543,059 shares during the last quarter. Aberdeen Group plc grew its stake in Alphatec by 44.1% in the 3rd quarter. Aberdeen Group plc now owns 1,712,328 shares of the medical technology company’s stock worth $17,671,000 after buying an additional 523,747 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Alphatec in the 2nd quarter worth approximately $3,092,000. 66.35% of the stock is owned by institutional investors.

Alphatec Stock Up 2.4%

The stock’s 50 day simple moving average is $9.65 and its 200 day simple moving average is $10.08.

Alphatec (NASDAQ:ATEC – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Alphatec had a negative net margin of 10.35% and a negative return on equity of 6,752.24%. The company had revenue of $221.17 million for the quarter, compared to analysts’ expectations of $225.16 million. During the same quarter last year, the business posted $0.03 EPS. The business’s quarterly revenue was up 12.6% compared to the same quarter last year. As a group, sell-side analysts expect that Alphatec Holdings, Inc. will post -0.40 earnings per share for the current year.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc. is a medical technology company focused on developing and marketing products for spine surgery. Its offerings are intended to support the surgical treatment of spinal disorders and include implants, biologics, instruments and access systems, along with technologies designed to assist surgeons during procedures. The company’s product portfolio includes solutions for several surgical approaches and stages of spine care, including systems for planning, accessing and instrumenting the spine.

Featured Stories

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.